The Food and Drug Administration (FDA) inspected the UCLA Health, UCLA Blood & Platelet Center in Los Angeles on April 15, reviewing blood and blood product operations, according to the agency’s data.
The final report concluded there were no management issues at UCLA Health, UCLA Blood & Platelet Center requiring corrective action.
The FDA periodically inspects facilities nationwide to determine whether workplaces and products comply with FDA-regulated standards aimed at supporting public health. Inspection outcomes are later made publicly available.
The FDA’s website states the government agency is chiefly tasked with overseeing the safety and quality of human and animal medications, biological products, medical supplies and tobacco products.
Information for this article is sourced from the U.S. Food and Drug Administration. The original data can be accessed here.
